What counts as a recurrent UTI?
Recurrent urinary tract infections can disrupt sleep, intimacy, work and travel. Worrying about the next episode is understandable. A useful prevention plan starts by checking what is causing your symptoms.
In adults, recurrent UTI usually means two or more infections in six months, or three or more in a year. A new infection after recovery is called reinfection. A return of the same organism may be a relapse and can prompt a search for a persisting cause.
Burning when passing urine, urgency, frequency and lower abdominal discomfort can suggest a bladder infection. Cloudy or strong-smelling urine alone does not establish the diagnosis. Symptoms may also overlap with bladder pain syndrome, vaginal dryness and other conditions.
Recurrent kidney infections, infections in men, pregnancy, childhood infections and an uncertain cause need specialist advice. A prevention guide should never delay treatment of a new infection.
Sources: NICE NG112 recommendations; NHS: urinary tract infections and urgent advice.
Why do infections keep coming back?
Many episodes in otherwise healthy women are new infections. Sexual activity, low fluid intake and hormonal changes around menopause may contribute. Other people have an underlying problem that needs a different approach.
A review may consider:
- Incomplete bladder emptying, prostate problems or a high amount of urine left after passing water.
- Stones, a bladder diverticulum, a foreign body or, less commonly, an abnormal connection between organs.
- Catheter use, diabetes, reduced immunity or a neurological bladder condition.
- Blood in the urine, particularly when it persists or returns after infection treatment.
Bring previous urine-culture results and a list of antibiotics you have taken. Cultures help identify bacteria and which antibiotics are likely to work. A simple diary of symptoms and possible triggers can also help.
Not everyone needs a scan or cystoscopy. Bladder-emptying tests, ultrasound or cystoscopy are chosen according to the history and findings. Repeated symptoms with negative tests also deserve assessment for infection and alternative causes.
Everyday prevention: a useful starting point
Practical changes are worth discussing, although the evidence is stronger for some measures than others. UTIs are not a sign that someone is unclean.
- Drink enough to avoid dehydration. Follow any fluid restriction you have been given for heart or kidney disease.
- Avoid regularly putting off passing urine. Passing urine after sex is reasonable if intercourse is a trigger, although evidence that this prevents infection is limited.
- Use gentle washing; avoid vaginal douching and harsh antiseptics. Wipe from front to back.
- Review spermicide use and contraceptive methods if episodes appear linked to them.
- Manage constipation and discuss difficulty emptying the bladder.
- If you use a catheter, ask for a personalised catheter-care and infection plan.
These measures support care; they do not replace assessment or treatment when an infection develops.
Sources: NHS: urinary tract infections and urgent advice; EAU Guidelines on Urological Infections, 2026.
Vaginal oestrogen around and after menopause
Falling oestrogen levels can affect vaginal and urinary tissues. Local vaginal oestrogen may help reduce recurrent infections when appropriate, particularly when dryness or discomfort is also present.
This can be discussed with women, trans men and non-binary people with a female urinary system who are perimenopausal or postmenopausal. Creams, tablets, pessaries or a vaginal ring may be considered. Very little is absorbed into the bloodstream, but your clinician should review your medical history, including any previous breast cancer.
Systemic HRT should not be prescribed solely to prevent UTIs. Local treatment is normally reviewed within 12 months, or sooner if needed.
Sources: NICE NG112 recommendations; NICE NG112 evidence discussion.
Hiprex: an alternative to daily antibiotics
Hiprex is the brand name for methenamine hippurate. It is a urinary antiseptic which works in acidic urine. It may reduce the need for daily preventive antibiotics, but does not treat a new acute UTI.
NICE includes it as an option for suitable non-pregnant people with a female urinary system when applicable earlier measures have not helped enough. Any current infection must first be treated. Pregnancy, recurrent kidney infections, complicated lower UTIs, men and children require specialist advice.
The usual adult prescription is 1 g twice daily, but your prescriber decides whether it is suitable and which dose to use. Kidney and liver function, other conditions and medicines need checking. Hiprex is unsuitable in severe kidney failure and several other conditions, including gout and severe dehydration.
Arrange a review within six months, then at least annually. Seek medical advice for new UTI symptoms while taking it.
Sources: Hiprex 1 g tablets: UK product information; NICE NG112 recommendations.
D-mannose: what does the newer evidence show?
D-mannose is a sugar sold as a supplement. It has been studied because it may interfere with the way some bacteria attach to the bladder lining. A plausible mechanism does not necessarily mean a treatment prevents infections in practice.
The UK MERIT trial included 598 women. Participants took 2 g of D-mannose or a placebo each day for six months. A suspected UTI requiring medical attention occurred in 51.0% versus 55.7%, respectively. The difference was not statistically significant, and the researchers did not recommend routine use for prevention in that population.
NICE’s older self-care advice notes that some non-pregnant people may wish to try D-mannose. That should not be read as proof of benefit. Discuss its cost and sugar content, especially if you have diabetes, and avoid using it in place of assessment or established prevention options.
Sources: Hayward et al., JAMA Internal Medicine, 2024 — MERIT trial; NICE NG112 recommendations.
Probiotics: an uncertain benefit
Probiotics containing Lactobacillus have been studied because bacteria in the vagina and gut may influence UTI risk. Results remain inconsistent. The strain and whether a product is taken orally or used vaginally may matter; products are not interchangeable.
NICE describes the prevention evidence as inconclusive. Probiotics should not be presented as a proven cure or used instead of treatment for an active infection. There is no established basis for assuming that a product with a higher bacterial count will prevent more UTIs.
Sources: NICE NG112 recommendations; EAU Guidelines on Urological Infections, 2026.
Preventive antibiotics: choosing and reviewing carefully
Preventive antibiotics can reduce recurrences, but the benefits must be weighed against side effects and antibiotic resistance. There are two main approaches:
- A single dose linked to a trigger, such as intercourse, for suitable patients.
- A daily low dose, considered when appropriate earlier measures have not worked or are unsuitable.
The choice depends on previous cultures, allergies, kidney function, other medicines and pregnancy status. Options in guidance include nitrofurantoin, trimethoprim and selected alternatives. Do not start leftover antibiotics or change a prescription yourself.
A new infection during prevention needs medical advice and may need a different antibiotic. Preventive prescriptions should be reviewed at least every six months so you and your clinician can decide whether to continue, change or stop.
Sources: NICE NG112 recommendations; MHRA: nitrofurantoin lung and liver safety advice.
Bladder instillations for recurrent UTIs and bladder pain
If infections keep returning or bladder discomfort persists between episodes, a specialist assessment can help distinguish recurrent bacterial infection from bladder pain syndrome and other causes. Bladder pain does not always mean infection. Negative urine tests alone do not establish a diagnosis of bladder pain syndrome.
For recurrent UTIs
Instillations containing hyaluronic acid, alone or with chondroitin sulphate, may be considered when less invasive preventive measures have not helped enough. They aim to support the bladder’s protective lining. Some studies suggest fewer infections and longer gaps between episodes, but evidence remains limited. The EAU recommendation is weak, and further research is needed.
For bladder pain syndrome
These treatments may also help some people with persistent bladder-related pain, urgency and frequency after infection and other causes have been assessed. Response varies, and treatment is tailored to the individual.
What treatment involves
A solution is placed in the bladder through a thin catheter, usually as a planned course of outpatient visits. Your clinician will discuss expected benefits, alternatives, costs and possible catheter-related discomfort or infection.
Read our iAluRil bladder instillation clinic guide to meet Jade and Kay, learn what to expect, and understand your care under Mr Shahzad’s clinical leadership.
Meet your bladder instillation team
Jade and Kay provide nursing care and support at the iAluRil clinic, under Mr Shahzad’s clinical leadership.
iAluRil clinic
iAluRil clinic
Sources: EAU Guidelines on Urological Infections; EAU bladder pain syndrome management; EAU bladder pain syndrome assessment.
Uromune (MV140): a specialist option under investigation
Uromune is a spray placed under the tongue containing inactivated bacteria. It aims to help the immune system prevent further infections. It is sometimes described as a UTI vaccine.
A placebo-controlled study randomised 240 women to MV140 or placebo. The active-treatment groups had fewer infections, but the study was relatively small and followed participants for one year. Further large studies are needed to establish longer-term benefits and which patients are most likely to benefit.
Any proposed use needs a specific discussion about the evidence, alternatives, unlicensed status, supply and follow-up. Its inclusion here does not confirm that it is available from Birmingham Advanced Urology. It does not replace treatment of an active infection.
Sources: Lorenzo-Gómez et al., NEJM Evidence, 2022 — MV140 trial; EAU Guidelines on Urological Infections, 2026; NHS Right Decisions: example Uromune named-patient pathway.
Putting a prevention plan together
- Check the diagnosis. Review the pattern, cultures, triggers and any warning signs.
- Address contributing factors. Discuss hydration, bladder emptying, contraception, constipation and vaginal oestrogen when appropriate.
- Choose prevention together. Trigger-related antibiotics, Hiprex or a trial of daily antibiotics may suit different situations.
- Plan reviews and breakthrough treatment. Know when your prescription will be reassessed and who to contact if symptoms return.
D-mannose and probiotics have weaker or inconclusive evidence. Uromune belongs in a separate specialist discussion, rather than a routine final step in the NICE pathway. Men, pregnant people, catheter users and people with kidney infections or other complicating factors need an individual plan.
Sources: NICE NG112 recommendations; EAU Guidelines on Urological Infections, 2026.
When to seek urgent help
Seek an urgent GP appointment or NHS 111 advice for fever or shaking chills, pain in the back beneath the ribs, vomiting, blood in the urine, worsening symptoms, or UTI symptoms during pregnancy. Seek prompt advice too if you are a man, use a catheter, have diabetes or reduced immunity, or symptoms are not improving with treatment.
Call 999 or go to A&E for new confusion, marked drowsiness or difficulty speaking. Sudden inability to pass urine also needs immediate medical assessment. Do not wait for a routine private appointment.
Recurrent UTI assessment in Birmingham
Mr Syed Ali Shahzad, Consultant Urological and Robotic Surgeon (FRCS Urol, FEBU, GMC 6071731), provides consultant-led assessment across Birmingham, Worcestershire and the West Midlands.
Appointments are available at The Harborne Hospital, The Priory Hospital, Droitwich Spa Hospital, Spire Little Aston, West Midlands Hospital and Stourside Hospital. Self-pay patients can enquire without a GP referral. Initial consultations are from £200; see current fees and insurance information and confirm costs when booking.
Bring recent culture results, a list of medicines and antibiotics, and a short symptom diary. The Patient Guide explains how to prepare. You can also explore Bladder Care, bladder disorders and the iAluRil bladder instillation clinic guide.
Arrange a consultation
Contact the secretary team for your preferred hospital through our appointment page. For HCA enquiries, contact Yasmin Khan on +44 7866 009874 or Yasmin.Khan@hcaconsultant.co.uk.
Frequently asked questions
Is Hiprex an antibiotic?
Hiprex is a urinary antiseptic, methenamine hippurate. It is used for prevention in suitable patients and is an alternative to daily antibiotics in NICE guidance. It does not treat a new acute UTI.
Should I take D-mannose every day?
The large UK MERIT trial did not show a clear benefit over placebo. Discuss the evidence, cost and sugar content with your clinician; it should not replace established prevention or treatment.
Do probiotics cure recurrent UTIs?
No. Evidence that they prevent recurrent UTIs remains inconclusive. They do not treat an active infection.
Is Uromune routinely available on the NHS?
No. Uromune is unlicensed in the UK and access depends on selected specialist arrangements. It is not a standard NICE prevention recommendation; the 2026 EAU guideline restricts immunomodulatory prevention to a well-regulated clinical trial.
Do men with recurrent UTIs need different care?
Recurrent UTIs in men warrant specialist assessment. Prostate health, bladder emptying and other possible causes are considered, with tests chosen according to the findings.
Can I book privately without a GP letter?
Self-pay patients can request a consultation directly. Insured patients should check their policy and obtain any required authorisation.
References for patients, clinicians and writers
- NICE NG112 recommendations
- NICE NG112 evidence discussion
- Hiprex 1 g tablets: UK product information
- Hayward et al., JAMA Internal Medicine, 2024 — MERIT trial
- MHRA: nitrofurantoin lung and liver safety advice
- Lorenzo-Gómez et al., NEJM Evidence, 2022 — MV140 trial
- EAU Guidelines on Urological Infections, 2026
- NHS Right Decisions: example Uromune named-patient pathway
- NHS: urinary tract infections and urgent advice
For editors and clinicians: MERIT — DOI 10.1001/jamainternmed.2024.0264; MV140 randomised trial — DOI 10.1056/EVIDoa2100018. The earlier uncontrolled UK series by Yang and Foley is available at PubMed (DOI 10.1111/bju.14067); it should not be interpreted as a placebo-controlled trial.